In this August issue of the BJO, Sacchetti and colleagues performed a meta-analysis of previously published randomized controlled trials on the topical use of cyclo-sporine A for the therapy of dry eyes. They found that all cyclosporine A formulations proved safe for the treatment of dry eye disease, and that symptoms improved in 9 out of 9 trials, while tear function improved in 13 out of 18 studies. Topical therapy with cyclosporine A was not successful for dry eye disorders resulting from surgical procedures, contact lens use and thyroid orbitopathy. The authors concluded that although topical cyclosporine A was safe treatment for dry eye disorders, there was only limited evidence for its therapeutic efficacy. The authors state that standardised diagnostic criteria are warranted to assess the efficacy of topical cyclosporine A.
展开▼
